Spectral AI (MDAI) Q2 2024 earnings summary

Executive summary

• Achieved strong Q2 2024 revenue growth, advancing DeepView AI-driven wound assessment platform toward commercialization, with first UK sales expected later in 2024 and US FDA submission planned for 2025.

• Deployed five DeepView AI burn devices in the UK post-UKCA authorization, gathering real-world data and clinical feedback to inform broader rollout and commercialization strategies.

• Exceeded 85% enrollment in the US burn pivotal study, with 100% pediatric enrollment completed; expanded to 16 US clinical sites, supporting a 2025 FDA submission.

• Entered a memorandum of understanding with PolyNovo in Australia to support device deployment and future commercialization, and advanced the DeepView Snapshot M handheld device for military and first responder use.

• Added to the Russell Microcap Index, increased granted patents from 20 to 26, and established a healthcare IP-focused subsidiary, Spectral IP.

Financial highlights

• Q2 2024 R&D revenue rose 76% year-over-year to $7.5 million, driven by increased BARDA Project BioShield contract activity.

• Gross margin improved to 44.3% from 42.1% year-over-year, reflecting higher reimbursement rates.

• General and administrative expenses increased to $5.8 million, but as a percentage of revenue, fell to 77% from 112% year-over-year.

• Net loss narrowed to $2.9 million (16 cents/share) from $3.1 million (23 cents/share) year-over-year.

• Cash and equivalents were $6.9 million as of June 30, 2024, up from $4.8 million at year-end 2023.

Outlook and guidance

• Reiterated 2024 revenue guidance of approximately $28 million, a 55% increase over 2023, driven by BARDA contract work and handheld device development.

• Guidance excludes potential UK commercial sales and other DeepView commercialization contributions.

• Second half 2024 expected to see increased BARDA revenue as clinical trials ramp up.

• US commercialization to begin with burn centers post-FDA approval, followed by emergency departments; international expansion opportunities being explored.

• Management believes current cash, government contract proceeds, and equity facilities are sufficient to fund operations for at least one year beyond the financial statement release date.